Document Detail


Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
MedLine Citation:
PMID:  2273298     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Eight patients with myelodysplastic syndromes (MDS) and four patients with aplastic anemia (AA) were treated with recombinant erythropoietin (rEpo) to investigate its effect on the anemia of these patients. rEpo was administered by i.v. injection three times a week for at least four weeks. The doses were 3,000, 6,000, or 12,000 U/day. Despite an elevated "endogenous" Epo level, a greater than 1.5 g/dl increase in hemoglobin (Hb) concentration was observed in one patient with refractory anemia (RA), one patient with refractory anemia with excess of blasts (RAEB), and one patient with AA. A greater than 50% decrease in red cell transfusion requirement was observed in one patient with RA and one patient with AA. One RA patient and one AA patient have received rEpo as maintenance therapy for more than 64 and 100 weeks, respectively. They no longer need red cell transfusions and have had a normal Hb concentration and normal ferrokinetics. No side effect was seen. These results indicate that rEpo may benefit some patients with MDS and AA who are dependent on red cell transfusions while further studies will be necessary to elucidate the mechanism by which rEpo stimulates erythropoiesis and improves anemia in patients with these diseases.
Authors:
M Bessho; I Jinnai; A Matsuda; M Saito; K Hirashima
Related Documents :
16163188 - Anemia in multiple myeloma.
19841268 - Interaction of malaria with a common form of severe thalassemia in an asian population.
10436298 - Sickle-cell disease in brazzaville, congo: genetical, hematological, biochemical and cl...
6156118 - Heterogeneity in beta 0 thalassemia from algeria: genetic, clinical and molecular studies.
24342758 - Comparison of the effectiveness of transcatheter aortic valve implantation in patients ...
8555748 - Positron-emission tomography in tardive dyskinesia.
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of cell cloning     Volume:  8     ISSN:  0737-1454     ISO Abbreviation:  Int. J. Cell Cloning     Publication Date:  1990 Nov 
Date Detail:
Created Date:  1991-02-25     Completed Date:  1991-02-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8308172     Medline TA:  Int J Cell Cloning     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  445-58     Citation Subset:  IM    
Affiliation:
First Department of Internal Medicine, Saitama Medical School, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Anemia, Aplastic / drug therapy*
Erythropoietin / adverse effects,  therapeutic use*
Female
Humans
Iron / blood
Male
Middle Aged
Myelodysplastic Syndromes / drug therapy*
Recombinant Proteins / adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin; 7439-89-6/Iron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Selectivity of hemoregulatory peptide (HP5b) action in culture.
Next Document:  Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesotheli...